Lucid Diagnostics (LUCD) AI Stock Analysis

• Market Cap: $166.05M
• Dividend Yield: N/A
• Average Volume (3M): 1.49M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.01
• Revenue Growth: 14.74%
• EPS Growth: 14.63%
• Country: US
• Employees: 72
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.10
• Shares Outstanding: 137,227,500
• 10 Day Avg. Volume: 1,382,728
• 30 Day Avg. Volume: 1,488,760
• PEG Ratio: 0.05
• Price to Book (P/B): 7.67
• Price to Sales (P/S): 9.52
• P/FCF Ratio: -0.92
• Enterprise Value/Market Cap: 0.99
• Enterprise Value/Revenue: 37.77
• Enterprise Value/Gross Profit: -58.71
• Enterprise Value/Ebitda: -3.03
• 1Y Price Target: $3.75
• Price Target Upside: 200.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 51 Neutral
• Price Target: $1.00 ▼(-20.00% Downside)

Lucid Diagnostics' overall score is primarily influenced by its financial challenges, despite strong revenue growth and positive earnings call sentiment. Technical indicators show a positive trend, but valuation concerns and high operational costs remain significant risks.

Positive Factors

Revenue Growth

Lucid Diagnostics' strong revenue growth indicates increasing adoption of its EsoGuard test, suggesting a growing market presence and potential for sustained expansion.

Strategic Partnerships

The partnership with Hoag Health System enhances distribution and credibility, potentially increasing EsoGuard's market penetration and long-term revenue streams.

Medicare Coverage Progress

Progress towards Medicare coverage could significantly boost EsoGuard's accessibility and reimbursement, driving long-term revenue growth and market expansion.

Negative Factors

High Leverage

High leverage increases financial risk, potentially impacting Lucid Diagnostics' ability to invest in growth opportunities and manage economic downturns.

Negative Cash Flow

Negative cash flows highlight liquidity challenges, limiting Lucid Diagnostics' ability to sustain operations and invest in future growth without external financing.

Operational Cost Challenges

High operational costs can strain financial resources, necessitating improved cost management for Lucid Diagnostics to achieve profitability and financial sustainability.

Lucid Diagnostics Business Overview & Revenue Model

Company Description

Lucid Diagnostics (LUCD) is a medical diagnostics company focused on developing and commercializing innovative solutions for the early detection and prevention of gastrointestinal diseases, particularly esophageal cancer. The company operates primarily in the healthcare sector, leveraging its proprietary technology to provide non-invasive diagnostic tests that aid physicians in identifying precancerous conditions. Its core product, the EsoGuard test, is designed to analyze cells from the esophagus to detect early signs of cancer and other related disorders, facilitating timely intervention and improving patient outcomes.

How the Company Makes Money

Lucid Diagnostics generates revenue primarily through the sale of its diagnostic tests, notably the EsoGuard test. The company operates a direct-to-consumer model as well as partnerships with healthcare providers, hospitals, and laboratories that utilize its testing services. Revenue is derived from test reimbursements through insurance companies and government programs, as well as out-of-pocket payments from patients. Additionally, Lucid Diagnostics may explore strategic partnerships with pharmaceutical companies and healthcare systems to expand its market reach and enhance its service offerings, which could further contribute to its revenue streams.

Lucid Diagnostics Financial Statement Overview

Summary

Lucid Diagnostics is experiencing rapid revenue growth, but this is overshadowed by significant profitability and cash flow challenges. The company is highly leveraged, which increases financial risk, especially given its negative margins and cash flows. While the revenue growth is promising, the company must focus on improving operational efficiency and managing its debt to achieve sustainable financial health.

Income Statement

Lucid Diagnostics has shown significant revenue growth in the TTM period, but the company is struggling with negative margins across the board. The gross profit margin, net profit margin, EBIT margin, and EBITDA margin are all negative, indicating that the company is not currently profitable. The high revenue growth rate is a positive sign, but the substantial losses suggest that the company needs to improve its cost management and operational efficiency.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio, indicating significant leverage, which poses a risk if the company cannot generate sufficient cash flow to service its debt. The return on equity is negative, reflecting the company's inability to generate profit from shareholders' equity. However, the equity ratio is relatively stable, suggesting that the company has a reasonable proportion of equity in its asset base.

Cash Flow

The cash flow statement shows negative operating and free cash flows, which are concerning as they indicate the company is not generating enough cash from its operations. The free cash flow to net income ratio is slightly above 1, suggesting that the company is managing its cash flow relative to its net losses. However, the overall negative cash flow growth and coverage ratios highlight liquidity challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.36M	4.35M	2.43M	377.00K	500.00K	0.00
Gross Profit	-2.81M	-3.92M	-6.05M	-3.24M	-85.00K	0.00
EBITDA	-54.36M	-44.34M	-49.75M	-54.23M	-27.41M	482.00
Net Income	-55.26M	-45.53M	-52.67M	-56.17M	-28.08M	-8.28M
Balance Sheet
Total Assets	38.67M	30.71M	27.27M	32.51M	59.00M	2.19M
Cash, Cash Equivalents and Short-Term Investments	31.12M	22.36M	18.90M	22.47M	53.66M	111.25K
Total Debt	27.55M	21.25M	15.26M	2.00M	0.00	0.00
Total Liabilities	30.81M	25.32M	29.58M	9.46M	4.26M	15.71M
Stockholders Equity	7.86M	5.39M	-2.31M	23.05M	54.74M	-13.52M
Cash Flow
Free Cash Flow	-23.03B	-44.79M	-33.04M	-30.59M	-18.53M	-5.63M
Operating Cash Flow	-23.03B	-44.14M	-32.82M	-29.68M	-17.67M	-5.63M
Investing Cash Flow	-118.61M	-646.00K	-221.00K	-4.11M	-862.00K	0.00
Financing Cash Flow	16.49B	48.25M	29.46M	2.61M	72.08M	5.58M

Lucid Diagnostics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LUCD, the sentiment is Positive. The current price of 1.25 is above the 20-day moving average (MA) of 1.13, above the 50-day MA of 1.12, and above the 200-day MA of 1.19, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 57.12 is Neutral, neither overbought nor oversold. The STOCH value of 68.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LUCD.

Lucid Diagnostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ICAD	60 Neutral	―	―	―	―	-4.15%	3.49%
XTNT	57 Neutral	$109.48M	-21.57	-9.80%	―	15.16%	-39.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LUCD	51 Neutral	$166.05M	―	-463.56%	―	14.74%	14.63%
OWLT	51 Neutral	$147.36M	―	―	―	36.81%	-74.26%
LUNG	43 Neutral	$68.05M	―	-66.88%	―	18.24%	4.81%
RCEL	42 Neutral	$105.41M	-2.04	-935.73%	―	38.32%	-1.31%

Lucid Diagnostics Corporate Events

Lucid Diagnostics Appoints John R. Palumbo to Board

On September 25, 2025, Lucid Diagnostics announced the appointment of John R. Palumbo to its Board of Directors, effective September 22, 2025. Palumbo brings 40 years of healthcare leadership experience, including guiding early-stage companies through commercial growth. His appointment is expected to support Lucid’s strategic initiatives as it approaches key commercial milestones, particularly in addressing unmet needs in cancer prevention with its EsoGuard product.

The most recent analyst rating on (LUCD) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.

Lucid Diagnostics Completes Public Offering for $26.9 Million

On September 11, 2025, Lucid Diagnostics Inc. announced the closing of its underwritten public offering of 28,750,000 shares of common stock at $1.00 per share, generating approximately $26.9 million in net proceeds. The funds are intended for working capital and general corporate purposes, with Canaccord Genuity LLC and BTIG, LLC acting as joint bookrunners, and Maxim Group LLC as co-manager. This offering, made under an existing shelf registration, aims to strengthen Lucid’s financial position and support its ongoing operations in the cancer prevention diagnostics market.

The most recent analyst rating on (LUCD) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.

Lucid Diagnostics Announces Public Stock Offering

On September 10, 2025, Lucid Diagnostics entered into an underwriting agreement for a public offering of its common stock, pricing each share at $1.00. The offering, managed by Canaccord Genuity LLC and BTIG, LLC, aims to raise $25 million, with potential to increase to $28.75 million if additional shares are purchased. The proceeds will support working capital and general corporate purposes, with the sale expected to close on September 11, 2025, subject to customary conditions.

The most recent analyst rating on (LUCD) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.

Lucid Diagnostics Earnings Call: Optimism Amid Challenges

Lucid Diagnostics Inc. recently held its earnings call, revealing a cautiously optimistic outlook for the company’s future. The call was marked by positive developments such as significant revenue growth and successful partnerships, alongside challenges like revenue recognition and high operational costs. The focus remains on achieving Medicare coverage, a key milestone for the company.

Lucid Diagnostics Reports Q2 2025 Earnings

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on cancer prevention, specifically targeting patients with gastroesophageal reflux disease (GERD) at risk of developing esophageal cancer. The company offers EsoGuard, a DNA assay, and EsoCheck, a non-invasive cell collection device, both based on patented technology licensed from Case Western Reserve University.

Lucid Diagnostics Advances Towards Medicare Coverage

Lucid Diagnostics reported financial results for the second quarter of 2025, with revenue of $1.2 million from 2,756 processed EsoGuard tests. The company ended the quarter with over $30 million in cash, extending its financial runway into 2026. Lucid is advancing towards securing Medicare coverage for EsoGuard, with a significant advisory committee meeting scheduled for September 4, 2025. The company has also initiated testing under a new insurance policy and partnered with Hoag to expand access to its testing programs. Additionally, Lucid joined the Russell 2000 and 3000 Indexes, enhancing its visibility among institutional investors.

The most recent analyst rating on (LUCD) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.